Quoin Pharmaceuticals Appoints Gordon Dunn as Chief

ASHBURN, Va., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company...

Related Keywords

,Jeff Ramson ,Michael Myers ,Gordon Dunn ,York University School Of Law ,Merrill Lynch ,Quoin Pharmaceuticals Ltd ,Nasdaq ,Company Or Quoin ,Company Annual Report On Form ,European Private Equity Group ,Stanford University ,Chief Financial Officer ,United Kingdom Based ,Chief Executive Officer ,Chief Financial ,Newsmith Capital ,Equity Capital ,New York University School ,Netherton Syndrome ,Peeling Skin Syndrome ,Palmoplantar Keratoderma ,Epidermolysis Bullosa ,Private Securities Litigation Reform Act ,Annual Report ,Nasdaq Qnrx ,Quoin Pharmaceuticals ,Nc ,